Eagle Pharmaceuticals has completed the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group of Paris, France. Barhemsys, the only FDA-approved treatment for postoperative nausea and vomiting (PONV), was approved in February 2020 and launched in the U.S. later that year. The move is intended to streamline Eagle's acute care business, while LXO Group plans to enhance its U.S. commercial capabilities by deploying a direct hospital sales force for Barhemsys alongside its existing portfolio. Proceeds from the transaction will support Eagle's ongoing business operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eagle Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9625702) on January 14, 2026, and is solely responsible for the information contained therein.